Moderna, Inc. — Director's Dealing 2021

Feb 12, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2021-02-09

Reporting Person: Hoge Stephen (President)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-09	Stock Option (Right to Buy)	$179.52	A	38428	Acquired	2031-02-09	Common Stock (38428)	Direct
2021-02-09	Restricted Stock Units	$0	A	8355	Acquired		Common Stock (8355)	Direct

Footnotes

F1: 25% of this option will vest and become exercisable on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

F2: 25% of the shares subject to this restricted stock unit award will vest on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter.